top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Dec 12, 2024
Regulatory Intelligence and the Role of Clinical Studies
Nov 6, 2023
What are the challenges in ensuring access to high-cost medicines?
Apr 8, 2022
Pharmaceutical Industry – focused on the future
Apr 7, 2022
ANVISA – Post-pandemic challenges and perspectives.
Sep 19, 2021
Medicine patents in Brazil – legislative changes and their impacts.
Sep 19, 2021
Brazilian regulation prices, and future trends
Sep 17, 2021
Innovation - The Driving Force of the Pharmaceutical Industry
Feb 9, 2021
Unraveling the Abbreviated Development Path
Feb 9, 2021
Publication of the Public Consultation for the review of RDC 200 - what is new?
Feb 9, 2021
NEW REGULATORY FRAMEWORK OF API
Feb 9, 2021
What is the purpose of clinical research on health products?
Feb 9, 2021
Incremental innovation: 5 suggestions that can contribute to your success
Feb 9, 2021
INCREMENTAL INNOVATION: How to prepare for the changes that will come with the revision of RDC 200
Feb 9, 2021
COVID-19: What facilities is ANVISA providing at this time of crisis?
Feb 9, 2021
Why are 24% of drug registrations still rejected?
Feb 9, 2021
Cannabis: challenges and opportunities
Feb 9, 2021
API, BPF and drug dossier - How to align the processes to ensure success in registration?
Feb 9, 2021
NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
Feb 9, 2021
Publication of the new API regulatory framework: what is essential to know?
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
